Severe acute respiratory syndrome vaccine efficacy in ferrets: Whole killed virus and adenovirus-vectored vaccines

Journal of General Virology

Volumn 89, Issue 9, 2008, Pages 2136-2146

  See, Raymond H ^a,f   Petric, Martin ^a   Lawrence, David J ^a   Mok, Catherine P Y ^a,f   Rowe, Thomas ^b,g   Zitzow, Lois A ^b,h   Karunakaran, Karuna P ^a   Voss, Thomas G ^b,i   Brunham, Robert C ^a   Gauldie, Jack ^c   Finlay, B Brett ^d   Roper, Rachel L ^e  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e EAST CAROLINA UNIVERSITY   (United States)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^h UNIVERSITY OF CHICAGO   (United States)

ⁱ TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; INACTIVATED VACCINE; LIVE VACCINE; RECOMBINANT VACCINE; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; HISTOPATHOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; TREATMENT RESPONSE; VIRUS DETECTION; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS TITRATION; VIRUS TRANSMISSION; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; EVALUATION; FERRET; GENE VECTOR; GENETICS; HUMAN; HUMAN ADENOVIRUS; IMMUNOLOGY; LUNG; PATHOLOGY; SERODIAGNOSIS; VIROLOGY;

ADENOVIRIDAE; MUSTELA; SARS CORONAVIRUS;

ADENOVIRUSES, HUMAN; ANIMALS; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; FERRETS; GENETIC VECTORS; HUMANS; LUNG; MALE; NEUTRALIZATION TESTS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VACCINES, ATTENUATED; VACCINES, INACTIVATED; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 52649147417     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.2008/001891-0     Document Type: Article

References (60)

1. Anton, I. M., Gonzalez, S., Bullido, M. J., Corsin, M., Risco, C., Langeveld, J. P. & Enjuanes, L. (1996). Cooperation between transmissible gastroenteritis coronavirus (TGEV) structural proteins in the in vitro induction of virus-specific antibodies. Virus Res 46, 111-124.
2. Bisht, H., Roberts, A., Vogel, L., Bukreyev, A., Collins, P. L., Murphy, B. R., Subbarao, K. & Moss, B. (2004). Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S A 101, 6641-6646.
3. Boots, A. M., Kusters, J. G., van Noort, J. M., Zwaagstra, K. A., Rijke, E., van der Zeijst, B. A. & Hensen, E. J. (1991). Localization of a T-cell epitope within the nucleocapsid protein of avian coronavirus. Immunology 74, 8-13.
4. Bukreyev, A., Lamirande, E. W., Buchholz, U. J., Vogel, L. N., Elkins, W. R., St Claire, M., Murphy, B. R., Subbarao, K. & Collins, P. L. (2004). Mucosal immunisation of African green monkeys ( Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 363, 2122-2127.
5. Cavanagh, D. (2003). Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus. Avian Pathol 32, 567-582.
6. Chan, K. H., Poon, L. L., Cheng, V. C., Guan, Y., Hung, I. F., Kong, J., Yam, L. Y., Seto, W. H., Yuen, K. Y. & Peiris, J. S. (2004). Detection of SARS coronavirus in patients with suspected SARS. Emerg Infect Dis 10, 294-299.
7. Che, X. Y., Di, B., Zhao, G. P., Wang, Y. D., Qiu, L. W., Hao, W., Wang, M., Qin, P. Z., Liu, Y. F. & other authors (2006). A patient with asymptomatic severe acute respiratory syndrome (SARS) and antigenemia from the 2003-2004 community outbreak of SARS in Guangzhou, China. Clin Infect Dis 43, e1-e5.
8. Chen, W., Yan, M., Yang, L., Ding, B., He, B., Wang, Y., Liu, X., Liu, C., Zhu, H. & other authors (2005). SARS-associated coronavirus transmitted from human to pig. Emerg Infect Dis 11, 446-448.
9. Chu, Y. K., Ali, G. D., Jia, F., Li, Q., Kelvin, D., Couch, R. C., Harrod, K. S., Hutt, J. A., Cameron, C. & other authors (2008). The SARS-CoV ferret model in an infection-challenge study. Virology 374, 151-163.
10. Collisson, E. W., Pei, J., Dzielawa, J. & Seo, S. H. (2000). Cytotoxic T lymphocytes are critical in the control of infectious bronchitis virus in poultry. Dev Comp Immunol 24, 187-200.
11. Cui, W., Fan, Y., Wu, W., Zhang, F., Wang, J. Y. & Ni, A. P. (2003). Expression of lymphocytes and lymphocyte subsets in patients with severe acute respiratory syndrome. Clin Infect Dis 37, 857-859.
12. Czub, M., Weingartl, H., Czub, S., He, R. & Cao, J. (2005). Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine 23, 2273-2279.
13. Darnell, M. E., Plant, E. P., Watanabe, H., Byrum, R., St Claire, M., Ward, J. M. & Taylor, D. R. (2007). Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets. J Infect Dis 196, 1329-1338.
14. Deming, D., Sheahan, T., Heise, M., Yount, B., Davis, N., Sims, A., Suthar, M., Harkema, J., Whitmore, A. & other authors (2006). Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med 3, e525.
15. Ding, Y., He, L., Zhang, Q., Huang, Z., Che, X., Hou, J., Wang, H., Shen, H., Qiu, L. & other authors (2004). Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARSCoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol 203, 622-630.
16. Enjuanes, L., Smerdou, C., Castilla, J., Anton, I. M., Torres, J. M., Sola, I., Golvano, J., Sanchez, J. M. & Pintado, B. (1995). Development of protection against coronavirus induced diseases. A review. Adv Exp Med Biol 380, 197-211.
17. Finlay, B. B., See, R. H. & Brunham, R. C. (2004). Rapid response research to emerging infectious diseases: lessons from SARS. Nat Rev Microbiol 2, 602-607.
18. Fleck, F. (2004). SARS virus returns to China as scientists race to find effective vaccine. Bull World Health Organ 82, 152-153.
19. Fouchier, R. A., Kuiken, T., Schutten, M., van Amerongen, G., van Doornum, G. J., van den Hoogen, B. G., Peiris, M., Lim, W., Stohr, K. & Osterhaus, A. D. (2003). Aetiology: Koch's postulates fulfilled for SARS virus. Nature 423, 240.
20. Glass, W. G., Subbarao, K., Murphy, B. & Murphy, P. M. (2004). Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J Immunol 173, 4030-4039.
21. Guan, Y., Zheng, B. J., He, Y. Q., Liu, X. L., Zhuang, Z. X., Cheung, C. L., Luo, S. W., Li, P. H., Zhang, L. J. & other authors (2003). Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302, 276-278.
22. Guan, Y. J., Tang, X. P., Zhang, F. C., Chen, Y. Q., Yin, C. B., Li, Y. M. & Zhong, N. S. (2005). Study of laboratory characteristic of 4 patients with sporadic severe acute respiratory syndrome in 2004. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 17, 332-334 (in Chinese).
23. Guo, J. P., Petric, M., Campbell, W. & McGeer, P. L. (2004). SARS corona virus peptides recognized by antibodies in the sera of convalescent cases. Virology 324, 251-256.
24. Hogan, R. J., Gao, G., Rowe, T., Bell, P., Flieder, D., Paragas, J., Kobinger, G. P., Wivel, N. A., Crystal, R. G. & other authors (2004). Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires stat1. J Virol 78, 11416-11421.
25. Hollander, M. & Wolfe, D. (1973). Nonparametric Statistical Methods. New York: Wiley.
26. Holmes, K. V. (2003). SARS coronavirus: a new challenge for prevention and therapy. J Clin Invest 111, 1605-1609.
27. Kim, T. W., Lee, J. H., Hung, C. F., Peng, S., Roden, R., Wang, M. C., Viscidi, R., Tsai, Y. C., He, L. & other authors (2004). Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J Virol 78, 4638-4645.
28. Kobinger, G. P., Figueredo, J. M., Rowe, T., Zhi, Y., Gao, G., Sanmiguel, J. C., Bell, P., Wivel, N. A., Zitzow, L. A. & other authors (2007). Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques. Vaccine 25, 5220-5231.
29. Lau, S. K., Woo, P. C., Li, K. S., Huang, Y., Tsoi, H. W., Wong, B. H., Wong, S. S., Leung, S. Y., Chan, K. H. & Yuen, K. Y. (2005). Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci U S A 102, 14040-14045.
30. Lawler, J. V., Endy, T. P., Hensley, L. E., Garrison, A., Fritz, E. A., Lesar, M., Baric, R. S., Kulesh, D. A., Norwood, D. A. & other authors (2006). Cynomolgus macaque as an animal model for severe acute respiratory syndrome. PLoS Med 3, e149.
31. Li, Z., Guo, X., Hao, W., Wu, Y., Ji, Y., Zhao, Y., Liu, F. & Xie, X. (2003). The relationship between serum interleukins and T-lymphocyte subsets in patients with severe acute respiratory syndrome. Chin Med J (Engl) 116, 981-984.
32. Marra, M. A., Jones, S. J., Astell, C. R., Holt, R. A., Brooks-Wilson, A., Butterfield, Y. S., Khattra, J., Asano, J. K., Barber, S. A. & other authors (2003). The genome sequence of the SARS-associated coronavirus. Science 300, 1399-1404.
33. Martina, B. E., Haagmans, B. L., Kuiken, T., Fouchier, R. A., Rimmelzwaan, G. F., Van Amerongen, G., Peiris, J. S., Lim, W. & Osterhaus, A. D. (2003). SARS virus infection of cats and ferrets. Nature 425, 915.
34. Navas-Martin, S. R. & Weiss, S. (2004). Coronavirus replication and pathogenesis: implications for the recent outbreak of severe acute respiratory syndrome (SARS), and the challenge for vaccine development. J Neurovirol 10, 75-85.
35. Olsen, C. W. (1993). A review of feline infectious peritonitis virus: molecular biology, immunopathogenesis, clinical aspects, and vaccination. Vet Microbiol 36, 1-37.
36. Olsen, C. W., Corapi, W. V., Jacobson, R. H., Simkins, R. A., Saif, L. J. & Scott, F. W. (1993). Identification of antigenic sites mediating antibody-dependent enhancement of feline infectious peritonitis virus infectivity. J Gen Virol 74, 745-749.
37. Reed, L. & Muench, H. (1938). A simple method of estimating fifty percent endpoints. Am J Hyg 27, 493-497.
38. Rockx, B., Sheahan, T., Donaldson, E., Harkema, J., Sims, A., Heise, M., Pickles, R., Cameron, M., Kelvin, D. & Baric, R. (2007). Synthetic reconstruction of zoonotic and early human severe acute respiratory syndrome coronavirus isolates that produce fatal disease in aged mice. J Virol 81, 7410-7423.
39. Rota, P. A., Oberste, M. S., Monroe, S. S., Nix, W. A., Campagnoli, R., Icenogle, J. P., Penaranda, S., Bankamp, B., Maher, K. & other authors (2003). Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300, 1394-1399.
40. Schmidt, N. & Emmons, R. (1989). Diagnostic procedures for viral, rickettsial and chlamydia infections. In Cell Culture Procedures for Diagnostic Virology, pp. 81-82. Edited by N. Schmidt. Washington, DC: American Public Health Association.
41. See, R.H., Roper, R. L., Brunham, R. C. & Finlay, B. B. (2005). Rapid response research - SARS coronavirus vaccines and application of processes to other emerging infectious diseases. Curr Immunol Rev 1, 185-200.
42. See, R. H., Zakhartchouk, A. N., Petric, M., Lawrence, D. J., Mok, C. P., Hogan, R. J., Rowe, T., Zitzow, L. A., Karunakaran, K. P. & other authors (2006). Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J Gen Virol 87, 641-650.
43. Seo, S. H., Wang, L., Smith, R. & Collisson, E. W. (1997). The carboxyl-terminal 120-residue polypeptide of infectious bronchitis virus nucleocapsid induces cytotoxic T lymphocytes and protects chickens from acute infection. J Virol 71, 7889-7894.
44. Skowronski, D. M., Astell, C., Brunham, R. C., Low, D. E., Petric, M., Roper, R. L., Talbot, P. J., Tam, T. & Babiuk, L. (2005). Severe acute respiratory syndrome (SARS): a year in review. Annu Rev Med 56, 357-381.
45. Stohlman, S. A., Kyuwa, S., Polo, J. M., Brady, D., Lai, M. M. & Bergmann, C. C. (1993). Characterization of mouse hepatitis virus- specific cytotoxic T cells derived from the central nervous system of mice infected with the JHM strain. J Virol 67, 7050-7059.
46. Stohlman, S. A., Bergmann, C. C., van der Veen, R. C. & Hinton, D. R. (1995). Mouse hepatitis virus-specific cytotoxic T lymphocytes protect from lethal infection without eliminating virus from the central nervous system. J Virol 69, 684-694.
47. Subbarao, K., McAuliffe, J., Vogel, L., Fahle, G., Fischer, S., Tatti, K., Packard, M., Shieh, W. J., Zaki, S. & Murphy, B. (2004). Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 78, 3572-3577.
48. ter Meulen, J., Bakker, A. B., van den Brink, E. N., Weverling, G. J., Martina, B. E., Haagmans, B. L., Kuiken, T., de Kruif, J., Preiser, W. & other authors (2004). Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 363, 2139-2141.
49. To, K. F., Tong, J. H., Chan, P. K., Au, F. W., Chim, S. S., Chan, K. C., Cheung, J. L., Liu, E. Y., Tse, G. M. & other authors (2004). Tissue and cellular tropism of the coronavirus associated with severe acute respiratory syndrome: an in situ hybridization study of fatal cases. J Pathol 202, 157-163.
50. Wang, M., Jing, H. Q., Xu, H. F., Jiang, X. G., Kan, B., Liu, Q. Y., Wan, K. L., Cui, B. Y., Zheng, H. & other authors (2005). Surveillance on severe acute respiratory syndrome associated coronavirus in animals at a live animal market of Guangzhou in 2004. Zhonghua Liu Xing Bing Xue Za Zhi 26, 84-87 (in Chinese).
51. Weingartl, H., Czub, M., Czub, S., Neufeld, J., Marszal, P., Gren, J., Smith, G., Jones, S., Proulx, R. & other authors (2004). Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol 78, 12672-12676.
52. Weiss, R. C. & Scott, F. W. (1981). Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever. Comp Immunol Microbiol Infect Dis 4, 175-189.
53. Wesseling, J. G., Godeke, G. J., Schijns, V. E., Prevec, L., Graham, F. L., Horzinek, M. C. & Rottier, P. J. (1993). Mouse hepatitis virus spike and nucleocapsid proteins expressed by adenovirus vectors protect mice against a lethal infection. J Gen Virol 74, 2061-2069.
54. WHO (2004a). Annex Table 2. Deaths by cause, sex and mortality stratum in WHO regions, estimates for 2002. http://www.who.int/whr/2004/ en/09_annexes_en.pdf
55. WHO (2004b). Update 4: Review of probable and laboratory-confirmed SARS cases in southern China. Epidemic and Pandemic Alert and Response, http://www.who.int/csr/don/2004_01_27/en/
56. Yang, Z. Y., Kong, W. P., Huang, Y., Roberts, A., Murphy, B. R., Subbarao, K. & Nabel, G. J. (2004). A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428, 561-564.
57. Ying, W., Hao, Y., Zhang, Y., Peng, W., Qin, E., Cai, Y., Wei, K., Wang, J., Chang, G. & other authors (2004). Proteomic analysis on structural proteins of Severe Acute Respiratory Syndrome coronavirus. Proteomics 4, 492-504.
58. Zakhartchouk, A. N., Liu, Q., Petric, M. & Babiuk, L. A. (2005). Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines. Vaccine 23, 4385-4391.
59. Zheng, B. J., Wong, K. H., Zhou, J., Wong, K. L., Young, B. W., Lu, L. W. & Lee, S. S. (2004). SARS-related virus predating SARS outbreak, Hong Kong. Emerg Infect Dis 10, 176-178.
60. Zitzow, L. A., Rowe, T., Morken, T., Shieh, W. J., Zaki, S. & Katz, J. M. (2002). Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J Virol 76, 4420-4429.